HK1068546A1 - Combination therapy comprising zd6474 and taxane - Google Patents

Combination therapy comprising zd6474 and taxane

Info

Publication number
HK1068546A1
HK1068546A1 HK05100883A HK05100883A HK1068546A1 HK 1068546 A1 HK1068546 A1 HK 1068546A1 HK 05100883 A HK05100883 A HK 05100883A HK 05100883 A HK05100883 A HK 05100883A HK 1068546 A1 HK1068546 A1 HK 1068546A1
Authority
HK
Hong Kong
Prior art keywords
taxane
combination therapy
therapy
combination
Prior art date
Application number
HK05100883A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1068546A1 publication Critical patent/HK1068546A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05100883A 2001-11-08 2005-02-03 Combination therapy comprising zd6474 and taxane HK1068546A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (1)

Publication Number Publication Date
HK1068546A1 true HK1068546A1 (en) 2005-04-29

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100883A HK1068546A1 (en) 2001-11-08 2005-02-03 Combination therapy comprising zd6474 and taxane

Country Status (23)

Country Link
US (2) US20050043395A1 (es)
EP (1) EP1446124B1 (es)
JP (1) JP4694127B2 (es)
KR (1) KR100959607B1 (es)
CN (1) CN1298328C (es)
AR (1) AR037346A1 (es)
AT (1) ATE335488T1 (es)
AU (1) AU2002337382B2 (es)
BR (1) BR0213906A (es)
CA (1) CA2464758C (es)
CY (1) CY1106259T1 (es)
DE (1) DE60213845T2 (es)
DK (1) DK1446124T3 (es)
ES (1) ES2269769T3 (es)
GB (1) GB0126879D0 (es)
HK (1) HK1068546A1 (es)
IL (2) IL161744A0 (es)
MX (1) MXPA04004355A (es)
NO (1) NO328048B1 (es)
NZ (1) NZ532525A (es)
PT (1) PT1446124E (es)
WO (1) WO2003039551A1 (es)
ZA (1) ZA200403455B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676845B1 (en) 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
MXPA02009891A (es) * 2000-04-07 2003-03-27 Astrazeneca Ab Compuestos de quinazolina.
AU2003202094B2 (en) * 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PT1562955E (pt) 2002-11-04 2008-05-05 Astrazeneca Ab Derivados de quinazolina como inibidores da scr tirosina-cinase
JP2006517575A (ja) * 2003-02-13 2006-07-27 アストラゼネカ アクチボラグ 組合せ療法
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2006035204A2 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Combination comprising zd6474 and an imatinib
EP2277595A3 (en) * 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009138781A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
JP2000510460A (ja) * 1996-04-26 2000-08-15 マゲイニン・ファーマシューティカルズ・インコーポレーテッド スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
CA2362937C (en) * 1999-02-24 2011-03-22 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
NZ514918A (en) * 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
EP1676845B1 (en) * 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
NZ537753A (en) * 2002-08-09 2008-04-30 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
JP2006517575A (ja) * 2003-02-13 2006-07-27 アストラゼネカ アクチボラグ 組合せ療法
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
WO2006035204A2 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Combination comprising zd6474 and an imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
US20050043395A1 (en) 2005-02-24
ZA200403455B (en) 2005-08-29
ES2269769T3 (es) 2007-04-01
IL161744A (en) 2012-01-31
EP1446124B1 (en) 2006-08-09
US20120252827A1 (en) 2012-10-04
NO328048B1 (no) 2009-11-16
AU2002337382B2 (en) 2008-06-12
IL161744A0 (en) 2005-11-20
GB0126879D0 (en) 2002-01-02
DE60213845D1 (de) 2006-09-21
NO20042365L (no) 2004-06-07
PT1446124E (pt) 2006-12-29
CN1298328C (zh) 2007-02-07
DE60213845T2 (de) 2007-03-29
CA2464758A1 (en) 2003-05-15
CN1612738A (zh) 2005-05-04
WO2003039551A1 (en) 2003-05-15
DK1446124T3 (da) 2006-11-13
AR037346A1 (es) 2004-11-03
MXPA04004355A (es) 2004-08-11
ATE335488T1 (de) 2006-09-15
NZ532525A (en) 2006-11-30
CA2464758C (en) 2010-09-28
KR20050043779A (ko) 2005-05-11
EP1446124A1 (en) 2004-08-18
BR0213906A (pt) 2004-08-31
KR100959607B1 (ko) 2010-05-27
JP2005511597A (ja) 2005-04-28
JP4694127B2 (ja) 2011-06-08
CY1106259T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
HK1068546A1 (en) Combination therapy comprising zd6474 and taxane
GB0111872D0 (en) Therapeutic agents and methods
EP1463438A4 (en) ENDOMURAL THERAPY
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002346504A8 (en) Therapeutic protein and treatments
PL369510A1 (en) Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
GB0114014D0 (en) Compostion and use
GB0212405D0 (en) Composition and its therapeutic use
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB0119025D0 (en) Compounds and their therapeutic use
GB0108485D0 (en) Combination therapy
GB0101933D0 (en) Therapy
GB0115780D0 (en) Therapeutic molecules and uses thereof
EP1701736A4 (en) THERAPEUTIC AGENTS AND ITS USES
HU0200253D0 (en) Combination therapy
EP1367123A4 (en) NEUROTONIN AND ITS USE
SI1446124T1 (sl) Kombinacijska terapija, ki obsega ZD6474 in taksan
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
GB0130736D0 (en) Compounds and their therapeutic use
GB0128512D0 (en) Compounds and their therapeutic use
GB0124029D0 (en) Combination therapy
GB0130733D0 (en) Therapeutic compounds and their use in therapy
GB0116969D0 (en) Neuro-phototransduction device and treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131106